Abstract：
Center-involving diabetic macular edema (DME) is a leading cause of vision impairment in working-age adults. While its management is particularly challenging in a poorly compliant population, continuous innovation and the advent of new molecules have improved its outcome. The control of glycemia and of systemic aggravating factors remain essential to slow down progression of disease complications including DME. The indications for macular laser photocoagulation has progressively been phased out as a standard of care and replaced by local intraocular anti-VEGFs biologics and glucocorticoids (GCs). Intravitreal GCs in controlled-release drug delivery systems have allowed to reduce injection frequency and treatment burden. The non biodegradable Fluocinolone Acetonide (FAc) implant allows a long-lasting stabilization of both functional and anatomic improvements. However, adequate patient selection and monitoring through regular follow-up are essential for optimal results. Based on their experience and the latest literature, the aim of the present review is to provide international expert panel consensus on the place of the FAc implant in the treatment algorithm of DME, as well as its safety profile and how to manage it.
摘要：
中心累及的糖尿病性黄斑水肿（DME）是工作年龄成年人视力障碍的主要原因。虽然它的管理在依从性差的人群中尤其具有挑战性，不断创新和新分子的出现改善了其结果。控制血糖和全身加重因素对于减缓包括DME在内的疾病并发症的进展仍然至关重要。黄斑激光光凝的适应症已逐渐被逐步淘汰为护理标准，并由局部眼内抗VEGF生物制剂和糖皮质激素（GC）代替。控释药物递送系统中的玻璃体内GC已允许减少注射频率和治疗负担。不可生物降解的氟轻松（FAc）植入物允许功能和解剖改进的长期稳定。然而,适当的患者选择和通过定期随访进行监测对于获得最佳结果至关重要.根据他们的经验和最新的文献，本次审查的目的是就FAc植入物在DME治疗算法中的地位提供国际专家小组共识，以及它的安全性和如何管理它。
